Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Eligibility Criteria: * Patient must have suspected or confirmed newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria and must not have received more than one cycle of any myeloma treatment. * Patient must be considered ineligible for autologous stem cell transplantation by the treating physician because of their age (≥ 70 years) or aged 18 - 70 years with the presence of underlying medical conditions likely to have a negative impact on tolerability of high-dose chemotherapy with stem-cell transplantation, making them transplant ineligible, OR transplant-eligible and refusing stem-cell transplantation until first relapse or later. * Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization. * ≥ 1g/dL monoclonal protein (M-protein) on serum protein electrophoresis * Involved free light chain ≥ 10 mg/dL or ≥ 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (\<0.26 or \>1.65) * ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis * Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease) * Patient must be ≥ 18 years and \<80 years of age. * Patient must have an Eastern Cooperative Group (ECOG) Performance Status (PS) of 0-2 (PS 3 allowed if secondary to pain). * Patient must have IMWG Frailty Score \<2. * Patient must have the ability to understand and willingness to sign a…